Fiducient Advisors LLC Boosts Stake in Amgen Inc. (NASDAQ:AMGN)

Fiducient Advisors LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 17.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,297 shares of the medical research company’s stock after acquiring an additional 640 shares during the quarter. Fiducient Advisors LLC’s holdings in Amgen were worth $1,238,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Alpha Cubed Investments LLC lifted its stake in Amgen by 2.2% in the 4th quarter. Alpha Cubed Investments LLC now owns 125,384 shares of the medical research company’s stock valued at $36,113,000 after buying an additional 2,667 shares in the last quarter. Brighton Jones LLC lifted its stake in Amgen by 3.5% in the 4th quarter. Brighton Jones LLC now owns 23,476 shares of the medical research company’s stock valued at $6,762,000 after buying an additional 786 shares in the last quarter. Mission Wealth Management LP lifted its stake in Amgen by 8.9% in the 4th quarter. Mission Wealth Management LP now owns 12,553 shares of the medical research company’s stock valued at $3,616,000 after buying an additional 1,022 shares in the last quarter. WealthTrust Axiom LLC raised its holdings in Amgen by 6.3% in the 4th quarter. WealthTrust Axiom LLC now owns 4,793 shares of the medical research company’s stock valued at $1,381,000 after acquiring an additional 284 shares during the last quarter. Finally, Certuity LLC raised its holdings in Amgen by 49.6% in the 4th quarter. Certuity LLC now owns 2,372 shares of the medical research company’s stock valued at $683,000 after acquiring an additional 786 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Down 0.9 %

Shares of Amgen stock traded down $2.44 during trading on Tuesday, hitting $273.94. 2,476,256 shares of the stock were exchanged, compared to its average volume of 2,816,730. The stock has a market cap of $146.94 billion, a price-to-earnings ratio of 21.93, a price-to-earnings-growth ratio of 2.61 and a beta of 0.58. The firm’s 50-day moving average price is $274.76 and its 200 day moving average price is $281.37. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same period in the previous year, the company earned $4.09 EPS. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. As a group, analysts forecast that Amgen Inc. will post 19.43 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.29%. Amgen’s dividend payout ratio is currently 72.06%.

Analyst Ratings Changes

AMGN has been the subject of a number of recent research reports. The Goldman Sachs Group increased their price objective on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Oppenheimer reaffirmed an “outperform” rating and set a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Truist Financial reaffirmed a “buy” rating and set a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. Finally, TD Cowen lowered their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $297.40.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.